Corporate actions: asset sale, CEO changes, earnings, conferences
Tap title to read story
United States. Between March 9 and March 10, 2026, multiple publicly traded companies issued investor communications disclosing corporate actions. Alexander's announced a definitive agreement to sell its Rego Park I property to Northwell Health for $235.5 million gross, producing $202 million net proceeds. West Pharmaceutical's CEO Eric M. Green notified the board of his planned retirement pending successor hiring. Mesa Laboratories named Siddhartha Kadia as incoming CEO effective April 13, 2026. Velo3D scheduled fiscal 2025 results for March 24, 2026. ESS and ASP Isotopes confirmed participation in investor conferences and webcast presentations. Based on 7 articles reviewed and supporting research.
More context
Timeline
- 1. March 9, 2026 — Alexander's announced sale agreement for Rego Park I to Northwell Health.
- 2. March 9, 2026 — West Pharmaceutical's CEO Eric M. Green informed board of planned retirement.
- 3. March 9, 2026 — Mesa Laboratories announced CEO change; Siddhartha Kadia to assume role April 13, 2026.
- 4. March 9, 2026 — Velo3D scheduled its fiscal 2025 results release and earnings call for March 24, 2026.
- 5. March 10, 2026 — ESS and ASP Isotopes confirmed attendance and presentations at investor conferences (ROTH; Canaccord Genuity).
Why it matters
These corporate actions can impact your investments. If you own shares in Alexander's, West Pharmaceutical, Mesa Laboratories, Velo3D, ESS, or ASP Isotopes, keep an eye on market reactions. Check your portfolio and consider how these changes might affect your financial strategy.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
